Cullinan Oncology announced this morning that its Chief Financial Officer Jeff Trigilio will depart the company effective March 29. Following his departure, Trigilio agreed to support the company through a transition period.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CGEM:
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- CGEM Upcoming Earnings Report: What to Expect?
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Cullinan Oncology announces U.S. FDA clearance of IND for CLN-619
- Wedbush bullish on Cullinan Oncology, initiates with an Outperform
